Hancock Mark sold $9.4M of PACS
Hancock Mark sold 186,696 shares of PACS Group, Inc. (PACS) at an average of $50.45 ($50.38–$51.44, $9.42M total) across 2 trades on 2026-11-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale represents a $9.4M reduction in insider holdings, which may affect investor perception.
Market read
Insider sale could lead to short-term price decline; traders may watch for price reaction.
What to watch
Potential tax planning or diversification motives for the insider.
Background
SEC Form 4 filing discloses insider transactions; required for directors and large shareholders.
Ticker impact
Director and 10% owner Hancock Mark sold 186,696 shares for $9.4M via a Form 4 filing.
likely downward pressure as market prices in the insider sale
A large insider sale by a director can be interpreted as lack of confidence, prompting short-term sell pressure.
Market effects
Minimal impact on the broader sector; primarily company-specific.
US market only.
Low
Counterpoint
The sale could be a routine liquidity event unrelated to company outlook.
Key entities
- InsiderHancock Mark
Director and 10% owner of PACS Group, Inc.
- CompanyPACS Group, Inc.
Provider of patient access solutions.

